Exercise training and the immune response in lung cancer
Official title: EXERCISE AND THE IMMUNE RESPONSE IN LUNG CANCER
Run by Medical University of Graz · NCT07267000 · Data updated 2026-11-12
This study tests whether a 12-week moderate or high-intensity exercise program can change the immune markers in people with non-small cell or small cell lung cancer who are receiving standard care.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Medical University of Graz Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Graz) |
| Status | Recruiting |
| Started | April 1, 2026 |
| Main results expected | October 1, 2028 |
| Study ends | May 1, 2029 |
| Registry record updated | June 9, 2026 |
| Trial ID | NCT07267000 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with non-small cell or small cell lung cancer, ECOG 0-1, who can safely perform stationary cycling and have no contraindicating medical conditions.
✕Probably not a fit
Patients with advanced debility, contraindications to exercise, or those unable to complete the 12-week program may see no potential benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study compares two 12-week exercise programs—moderate-intensity continuous training and high-intensity interval training—against standard exercise recommendations in adults with non-small cell or small cell lung cancer. The goal is to see how these training regimens affect immune system markers, such as cytokine levels and peripheral blood mononuclear cell characteristics, in addition to usual cancer care. Participants must have a good performance status and be able to engage in stationary cycling, with safety monitoring in place. The study is led by the Medical University of Graz with collaboration from the Austrian Science Fund (FWF).
Why it matters
Potential benefit: If successful, participants may experience favorable immune changes that could support cancer treatment and overall health.
How similar studies have gone: Previous research suggests exercise can affect immune markers and inflammation, but direct benefits to tumor outcomes in lung cancer remain to be proven.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients suffering from non-small cell or small-cell lung cancer of any histologic subtype, irrespective of routine treatment regimen * ECOG 0 or 1 Exclusion Criteria: * Kachexia (BMI\<18.5) * instable bone metastases * orthopedic condition rendering the patient unable to ride a stationary bike * any medical contraindication for exercise and training * a living will against basic or advanced life support
Where it's running
-
Medical University of Graz
Graz, Austria Recruiting
Study contacts
- Principal investigator: Elisabeth Taucher, Dr. Dr. — Medical University of Graz
- Study coordinator: Lukas Spielbüchler, MEd, BEd
- Email: lukas.spielbuechler@medunigraz.at
- Phone: +43 699 10558825
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Ivonescimab in Neoadjuvant NSCLC: Testing a PD-1/VEGF Bi-specific
This study tests Ivonescimab, a PD-1/VEGF bispecific antibody, in people with non-small cell lung cancer to see if it works better or has different safety than standard PD-1 inhibitors before surgery.
-
Neoadjuvant Cemiplimab + Dupilumab in Early-Stage NSCLC
This study tests whether giving cemiplimab with dupilumab before surgery can be safe and help shrink tumors in people with early-stage non-small cell lung cancer.
-
Combining Cadonilimab with Stereotactic Radiotherapy for Brain Metastases Treatment
This study is testing if combining a new drug called Cadonilimab with targeted radiation therapy can help people with brain metastases from lung cancer feel better and have fewer side effects than current treatments.
-
Omitting radiation for advanced lung cancer patients who responded to treatment
This study is testing whether skipping radiation for patients with advanced lung cancer who have responded well to initial treatment can help reduce side effects while still keeping the cancer under control.
-
Outdoor resistance training for older adults
This trial tests a 6-week outdoor strength program using benches and a smartphone app to see if it’s safe, usable, and appealing for community-dwelling adults aged 65 and older.
-
Patient-specific MRD liquid biopsy for resected NSCLC
This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.